SENOTHERAPEUTIC AGENTS AND ALPHA-KLOTHO POLYPEPTIDES

Abstract: this document relates to methods and materials for assessing and/or using one or more senotherapeutic agents. in some cases, methods and materials for determining the efficacy of an anti-senescence treatment in a mammal (e.g., a human) are provided. for example, a level of one or more �-klotho polypeptides in a sample (e.g., a urine sample) from a mammal (e.g., a human) can be used to determine the efficacy of the one or more senotherapeutic agents. in some cases, methods and materials for treating a mammal (e.g., a human) having a disease or disorder characterized by a reduced level of an �-klotho polypeptide are provided. for example, one or more senotherapeutic agents and/or one or more inhibitors of a senescence-associated secretory phenotype (sasp) polypeptide can be administered to a mammal (e.g., a human) to increase a level of �-klotho polypeptides within the mammal.

Inventor(s): Yi Zhu, James L. Kirkland, Tamar Tchkonia, Nino Giorgadze, Tamar Pirtskhalava

CPC Classification: A61K31/506 (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms ; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles ; soap compositions ))

Search for rejections for patent application number 20250170129